FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, particularly to an antibody or an antigen-binding fragment thereof, specifically binding with a hepatocyte growth factor receptor (c-Met). Also disclosed are a nucleic acid molecule encoding said antibody, an expression vector and a host cell containing said nucleic acid molecule, compositions for detecting c-Met and preventing or treating cancer, containing said antibody. Disclosed are methods for detecting c-Met antigen using said antibody, method for treating or preventing cancer using said antibody.
EFFECT: invention allows effectively treating cancer associated with overexpression of c-Met.
27 cl, 20 dwg, 28 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| SPECIFIC TO MUCIN-1 POLYPEPTIDE AND ITS USE | 2021 |
|
RU2805840C1 |
| MODIFIED MITOCHONDRIA AND THEIR USE | 2019 |
|
RU2811467C2 |
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
